Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH001 versus placebo in treatment-resistant depression
NL-OMON53737Phase 2Completed
- Sponsor
- GH Research PLC
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in treatment-resistant depression (TRD) and major depressive disorder (MDD) comparing GH001 individualized dosing regimen with Placebo (2 arms). Primary endpoint: Mean change in MADRS from Baseline to Day 7. Started Aug 2024; status: completed.
02
Drugs
mebufotenin
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON53737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53737.